NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.
Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling.
Financial and other terms of the partnership were not disclosed.
"By partnering with Ambry Genetics to better inform patient care, we are able to provide clinicians a greater ability to learn about a cancer's molecular composition," Caris Founder and CEO David Halbert said in a statement.
Ambry CEO Aaron Elliot added, "Caris' molecular tests, combined with Ambry's germline genetic testing, give clinicians the most comprehensive, clinically relevant molecular profile on the market to guide treatment and management."
Ambry's panel analyzes 67 genes associated with an increased hereditary risk of cancer, including brain, breast, colon, ovarian, pancreatic, prostate, renal, and uterine cancers. The Aliso Viejo, California-based firm is part of Konica Minolta Precision Medicine. Caris' testing platform assesses DNA, RNA, and proteins in a patient's tumor to guide treatment decisions. The firm is based in Irving, Texas.